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Abstract
Background: Glyceryl trinitrate (GTN) has been shown to be able to relax the sphincter of Oddi (SO) both in
animals and humans. Theoretically, the use of these compounds during and after endoscopic retrograde
cholangiopancreatgraphy (ERCP) could relax the biliary and pancreatic sphincters, facilitating cannulation of
common bile duct (CBD) during the procedure, or minimizing potential pancreatic outflow obstruction after the
procedure. However, clinical trials evaluating the protective effect of GTN on the post-endoscopic retrograde
cholangiopancreatgraphy pancreatitis (PEP) have yielded inconclusive results. This meta-analysis is to systematically
assess the effect of prophylactic administration of glyceryl trinitrate (GTN) on the prevention of PEP and the effect
on the cannulation of bile ducts.
Methods: By searching PubMed (1966 to September 2009), CENTRAL (Cochrane Controlled trials Register; issue 3,
2009) and EMBASE.com (1984 to September 2009), two independent reviewers systematically identified prospective
randomized controlled trials (RCTs) detecting the effect of prophylactic GTN on the incidence of PEP and on the
cannulation of bile ducts. A meta-analysis of these clinical trials was then performed.
Results: There are 55/899(6.1%) patients suffering PEP in the treatment group versus 95/915(10.4%) patients in the
placebo group. The overall pooled risk of PEP was significantly lower in the GTN group than in the placebo group
(OR 0.56, 95% CI: 0.40 to 0.79, p = 0.001). Subgroup analyses suggested that GTN administered by the sublingual
form (OR 0.34,95% CI:0.16 to 0.75, p = 0.007) is more effective than transdermal route(OR 0.64,95% CI:0.40 to 1.01, p
= 0.05), and the protective effect of GTN was far more obvious in the centers with high incidence of PEP (OR 0.40,
95% CI:0.24 to 0.67, p = 0.0006) than those centers with a low incidence of PEP (OR 0.75, 95% CI: 0.47 to 1.20, p =
0.22). Additionally, the meta-analysis suggests that GTN was not helpful for the cannulation of bile ducts.
Conclusion: We concluded that prophylactic administration of GTN may significantly reduce the incidence of PEP
and not be helpful for the cannulation of bile ducts.
Background
Endoscopic retrograde cholangiopancreatography
(ERCP) is now well established in the diagnosis and
treatment of pancreatobiliary disease. Pancreatitis
remains one of the most feared complications of ERCP,
with a frequency ranging from 1 to 40 per cent depend-
ing partly on the chosen definition of pancreatitis [1].
The pathogenesis of ERCP-induced pancreatitis has not
been completely elucidated, but some risk factors were
recognized as independent predictors, including younger
age, female, pancreas divisum, sphincter of Oddi dys-
function, prior ERCP-induced pancreatitis, difficulty of
cannulation, and pancreatic duct injection [2]. An
obstructed outflow was also suggested as an important
initiating step in developing post-ERCP pancreatitis [3].
Several mechanical and pharmacological interventions
have been evaluated in the prevention of PEP.
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Prophylactic pancreatic stents have become standard of
care for reducing PEP in high-risk cases. In contrast,
trials of pharmacological therapy have generally yielded
disappointing results [4]. So far, no pharmacological
prophylaxis for PEP is widespread clinical use [5].
Glyceryl trinitrate (GTN) can reduce sphincter of
Oddi pressure [6], an effect that has been used to facili-
tate endoscopic removal of medium- and small-sized
stones from the biliary tract [7]. Theoretically, the use
of these compounds during and after ERCP could relax
the biliary and pancreatic sphincters, facilitating CBD
cannulation during the procedure, or minimize potential
pancreatic outflow obstruction after the procedure.
Unlike the other potentially beneficial drug therapies,
GTN has the advantage of being inexpensive and com-
paratively easily administered [3].
Despite these anticipated benefits, prospective clinical
trials evaluating effect of GTN on the incidence of PEP
and on the successful rate of cannulation of ducts have
yielded inconclusive results. So we intended to perform
a meta-analysis, aiming to evaluate whether prophylactic
use of GTN can reduce the incidence of PEP and/or
increase the successful rate of cannulation of ducts by
systematically reviewing the published randomized ther-
apeutic trials about this topic.
Methods
Literature Search
PubMed (1966 to September 2009), CENTRAL
(Cochrane Controlled trials Register; issue 3, 2009) and
EMBASE.com (1984 to September 2009) were searched
by adopting the following strategy “(endoscopy* or
ERCP* or endoscopic retrograde cholangiopancreatogra-
phy* or pancreatitis* or PEP* or post-ERCP pancreatitis*
or post-endoscopic retrograde cholangiopancreatography
pancreatitis* or cannulation*) AND (GTN* or glyceryl
trinitrate* or nitroglycerin*)”. The results were limited
to human studies and clinical trials without language
limited. The manual searching of reference lists from
potentially relevant papers was performed to identify
any additional studies that may have been missed using
the computer-assisted strategy. Before conducting this
analysis, we have sought expert advice on ERCP and
Evidence-based medicine, and they said that it is neces-
sary to perform this analysis to help make clinical
decision.
Selection Criteria and Assessment
Two investigators independently reviewed titles and
abstracts of all citations identified by the literature
search. Potentially relevant studies were retrieved and
selection criteria applied. The inclusive criteria were: (1)
studies that examine the effect of GTN on the incidence
of PEP and/or on the cannulation of ducts; (2) studies
that were prospective, randomized and placebo con-
trolled; (3) studies in humans; (4) date not duplicated in
another manuscript; (5) the age of patient population
should be over 18 years; (6) the patients were scheduled
to undergo ERCP; (7) co-interventions (including treat-
ment of complications) were allowed if administered
equally to all intervention groups. The following exclu-
sive selection criteria were set: (1) quasi-randomized
trials and non-randomized studies; (2) the raw data was
not completed; (3) repetitive reports; (4) difference of
co-interventions between intervention arms. Eligible
articles were reviewed and data were abstracted in a
duplicated and independent manner by two investiga-
tors. Included studies were assessed for methodological
quality in accordance with the Jadad composite scale.
According to this scale, low quality studies had a score
of ≤ 2 and high quality studies had a score of ≥ 3 [8].
Statistical Analysis
If several trials were available for a specific topic, meta-
analysis using the software Revman 4.2 (provided by the
Cochrane Collaboration, Oxford, UK) with a fixed
effects model and random effects model was performed.
Statistical heterogeneity between trials was evaluated by
the Cochran Chi-square test and defined at a P value
less than 0.05. Pooled odds ratio (OR) was calculated
using the general inverse variance (IV) fixed-effect
model. If results were heterogeneous (p < 0.05), a ran-
dom-effects model was employed. Pooled OR was pre-
sented as standard plots with 95 percent confidence
intervals (CI). In case of clinical heterogeneity concern-
ing study population and therapeutic modalities, pooling
was not implemented and the results were assessed
using subgroup analyses or descriptive statistics.
Result
Figure 1 shows details of study identification, inclusion,
and exclusion. The search on PubMed, Embase and
the Cochrane Library under the defined terms yielded
548 articles. Of these, we included 9 unique studies in
this meta-analysis. Additionally, there are two articles
without full-text available [9,10]. So seven randomized
controlled clinical trials were included for the meta-
analysis of the effect of GTN on the prevention of PEP
[1,3,11-15] and seven RCTs were included for the
meta-analysis of the effect of GTN on the cannulation
of bile ducts [1,3,11-13,16,17]. Characteristics of the 9
included randomized controlled trials (RCTs) are listed
in Table 1. Quality assessment by Jadad score revealed
that five included studies met 5/5 criteria, and four
studies met 4/5 criteria (Table 2), indicating that all
studies were of reasonable methodological and high
quality; none of the studies had any “fatal” methodolo-
gical flaws. It is worth mentioning that a study made
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by Wehrmann T et al was also included in the meta-
analysis of the effect of GTN on the incidence of PEP.
Although its title and abstract didn’t mention the out-
come of PEP, yet there was a report for the incidence
of PEP in its results [12].
Meta-analysis for the effect of GTN on the incidence of
PEP
Seven studies were finally included in the meta-analysis
for the effect of GTN on the incidence of PEP. In total,
the analysis comprised 1841 patients with 150 patients
suffering PEP. Among PEP-suffering patients, 55
patients were treated with GTN, whereas 95 patients
were treated with placebo. The route of GTN adminis-
tration differs remarkably in the trials and we con-
ducted a subgroup meta-analysis looking at the trials
where GTN was administered by transdermal patch or
by sublingual route. The chi-square test for heterogene-
ity on all seven studies was 6.09 (df = 6, P = 0.41), i.e.
no evidence of statistical heterogeneity was demon-
strated and a fixed effects analysis model was
performed.
The meta-analysis detected a significant difference
between the two arms with regard to the incidence of
post-ERCP pancreatitis (OR 0.56, 95%CI: 0.40 to 0.79,
p = 0.001) (Figure 2), showing that the risk of pancreati-
tis was significantly lower in the treatment group than
in the placebo group.
Because of the different ways of administrating GTN
that could influence the effectiveness of GTN, we per-
formed some subgroup meta-analysis of these trials
(Table 3). There are two articles regarding the sublin-
gual route in which there are 10/128 (7.8%) patients suf-
fering PEP in the treatment arm versus 26/132 (19.7%)
Figure 1 Flow of study identification, inclusion, exclusion.
Table 1 Characteristics of RCTs
First auther Year Location Sample size Intervention(treatment/control) Related outcomes Allocation
concealment
Sudhindran S 2001 UK 186 2 mg sublingual GTN 90/96 Control A and B ADEQUAT
Wehrmann T 2001 Germany 80 10 mg topical GTN 40/40 Control A and B NOT CLEAR
Ghori A 2002 UK 254 0.4-0.8 mg sublingualGTN128/126 Control B ADEQUATE
Moretó M 2003 Spain 144 15 mg transdermal GTN 71/73 Control A and B ADEQUATE
Talwar A 2005 UK 104 5 mg topical GTN52/52 Control B NOT CLEAR
Kaffes AJ 2006 Australia 318 5 mg transdermal GTN 155/163 Control A and B NOT CLEAR
Beauchant M 2008 France 208 < mg intravenous GTN 105/103 Control A and B NOT CLEAR
Nøjgaard C 2009 Norway 806 15 mg transdermal GTN 401/405 Control A and B ADEQUATE
Hao JY 2009 China 74 5 mg sublingual GTN 38/36 Control A NOT CLEAR
A: the outcome of PEP B:the outcome of cannulation
The definition of the post-ERCP pancreatitis
Sudhindran S Acute pancreatitis was defined as a serum amylase level greater than 1000 (normal range 5-300) units/ml
at 6 h in association with a visual analogue pain score of more than 5.
Wehrmann T Pancreatitis, defined according to published recommendations by Cotton PB et al (1991).
Moretó M Pancreatitis, defined according to published recommendations by Cotton PB et al (1991).
Kaffes AJ Pancreatitis, defined according to published recommendations by Cotton PB et al (1991).
Beauchant M Pancreatitis, defined according to published recommendations by Cotton PB et al (1991).
Nøjgaard C Pancreatitis, defined according to published recommendations by Cotton PB et al (1991).
Hao JY Post-ERCP pancreatitis could be defined as a disease with sustained pancreatitis symptoms (such as abdominal pain) and high-
amylase value over the normal value after ERCP.
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in the placebo arm; and there are three studies with
regard to the transdermal route in which there are 32/
626 (5.1%) patients suffering PEP in the treatment arm
versus versus 50/640 (7.8%) in the placebo arm. When
just analyzing the effect of sublingual GTN on the inci-
dence of PEP, we revealed a significant difference
between the two groups (OR 0.34, 95% CI: 0.16 to 0.75,
P = 0.007), but there was no statistical difference found
between the two groups when we just analyzed the
effect of transdermal GTN on the incidence of PEP (OR
0.64, 95% CI: 0.40 to 1.01, P = 0.05). And so if we put
the two results together, we could easily conclude that
the way of sublingual GTN is more effective than the
way of transdermal GTN for preventing the PEP,
although the later enrolled far more patients (sublingual
GTN 260 VS transdermal GTN 1266). The chi-square
test for heterogeneity of the two subgroup analysis was
P = 0.16 and P = 0.15, respectively, demonstrating no
evidence of statistical heterogeneity. We suggested that
investigation regarding the sublingual form for prevent-
ing PEP should be paid more attention to, and more
RCTs should be per-formed to further confirm the
effect of sublingual form on PEP.
Given the different definition of PEP may influence
the pooled effect, we performed a sensitivity analysis
including the five studies with the same definition of
PEP derived from the published recommendations by
Cotton PB et al [18], also detecting a significant protec-
tive effect of GTN against post-ERCP pancreatitis (OR
0.64, 95% CI: 0.43 to 0.94, P = 0.02). Through another
subgroup analysis, we discover that prophylactic use of
GTN before ERCP was very effectively against the
occurrence of PEP in those centers with high incidence
of PEP in the placebo arm (OR 0.40, 95% CI: 0.24 to
0.67, P = 0.0006). In contrast, prophylactic use of GTN
before ERCP was not helpful in the prevention of PEP
in those centers with low incidence of PEP (OR 0.75
95% CI: 0.47 to 1.20, P = 0.22). Because the overall inci-
dence of PEP in the placebo group was 10.4%, so we
adopted a decision that take 10.4% as the cut-off point
to stratify the trials (see Table 3).
Meta-analysis for the effect of GTN on the cannulation of
ducts
Seven studies were included in the meta-analysis of
GTN on the cannulation of bile ducts. Although not all
Figure 2 This figure revealed the overall effect of GTN on the incidence of PEP, when all of seven included RCTs are analyzed
together.
Table 2 Jadad quality scores of randomized controlled trials included in the meta-analysis





Sudhindran S CGL double clear reported 5 single center
Wehrmann T not clear double clear reported 4 single center
Ghori A not clear double clear reported 4 single center
Moretó M not clear double clear reported 4 single center
Talwar A CGL double clear reported 5 single center
Kaffes AJ CGL double clear reported 5 single center
Beauchant M centrally double clear reported 5 multicenter
Nøjgaard C adequate double clear reported 5 multicenter
Hao JY not clear double clear reported 4 single center
CGL: computer-generated list
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of the seven studies considered the successful rate of
cannulation as the major outcome, they all included
information about it. We respectively pooled the pri-
mary successful rate of cannulation of ducts before the
operation of sphincterotomy or pre-cut maneuver and
the overall successful rate of cannulation of ducts after
the operation of sphincterotomy or pre-cut maneuver.
At first, we must make it clear that although some arti-
cles don’t directly report the primary number of suc-
cessful cannulation, but we can get the number through
a subtraction that the overall number of successful can-
nulation subtracts the number of pre-cut maneuver
and/or sphincterotomy and if we finally can’t obtain the
primary number of successful cannulation, thus we
excluded these articles. All of seven included studies
adequately report the overall successful number of can-
nulation and the number was obtained from just five
included articles.
As for either the primary rate or the overall rate of
successful cannulation, there isn’t any benefit detected
between the treatment arm and the placebo arm. There
are five articles included with 900 patients for analyzing
the effect of GTN on the primary rate of cannulation,
and we don’t detect a significant difference (see Figure
3). There are seven articles included with 1294 patients
for analyzing the effect of GTN on the overall rate of
cannulation, we also can’t found any benefit from the
use of GTN (see Figure 4).
When we added the two articles [9,10] only with
abstract available to the seven included studies to ana-
lyze together and make some subgroup analysis, but it
was a pity that as we have seen in the Table 4, there
still was no benefit revealed for the cannulation. From
all these analysis above, we can make a conclusion that
the prophylactic use of GTN before ERCP may not be
able to help facilitate cannulation of bile ducts and
reduce the use of pre-cut maneuver.
Adverse effect of using GTN
Sudhindran S, et al reported that the only significant
adverse effects attributable to GTN were hypotension
and headache. More than 50% of the treatment group
suffered a period of hypotension (systolic brachial pres-
sure lower than 100 mmHg) in the immediate post-pro-
cedural period, compared with 5% of the placebo group.
However, the hypotension responded in all cases to an
Table 3 subgroup and sensitivity analysis of the effect of GTN on the prevention of PEP
Trials Subgroup(N) Odds ratio (95%) CI Z P value Heterogeneity
x2 P I2,%
The overall effect of GTN on the incidence of PEP
all forms 7 studies(n = 1814) 0.56 [0.40, 0.79] 3.29 0.001 6.09 0.41 1.4
Different forms
sublingual form 2 studies(n = 260) 0.34 [0.16, 0.75] 2.70 0.007 0.24 0.62 0
transdermal form 3 studies(n = 1266) 0.64 [0.40, 1.01] 1.93 0.05 3.77 0.15 47.0
Different definition of PEP
the same criteria 5 studies(n = 1554) 0.64 [0.43, 0.94] 2.25 0.02 3.80 0.43 0
Sudhindran S 1 studies(n = 186) 0.39 [0.15, 1.00]
Hao JY 1 studies(n = 74) 0.26 [0.06, 1.04]
Different incidence of PEP in the placebo group(10.4% as the cut-off point to stratify the trials)
low incidence 3 studies(n = 1204) 0.75 [0.47, 1.20] 1.22 0.22 1.42 0.49 0
high incidence 4 studies(n = 610) 0.40 [0.24, 0.67] 3.44 0.0006 1.88 0.60 0
Figure 3 This figure revealed the primary effect of GTN on the successful rate of cannulation.
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intravenous infusion of crystalloids. And there are a
small number of patients in the treatment group com-
plained of headache.
Moretó M, et al found that both headache and hypo-
tension are more often occurred in the treatment group
than in the placebo group, and responded to conven-
tional treatment. In addition, there are several patients
having nausea and/or vomiting. Arthur JK, et al also
found headache and hypotension are more frequently
seen in the treatment arm. And the side effect of rash
occurred in this study.
Beauchant M, et al and Nøjgaard C, et al also found
headache and hypotension are more frequent in the GTN
group. However, Ghori A, et al and Talwar a, et al revealed
no adverse effect attributable to GTN in their studies.
In aggregate, hypotension and headache often occur
and are more frequent seen in the GTN group. How-
ever, they easily managed and responded to conven-
tional treatment. Additionally, other relatively less
symptoms include nausea, vomiting and rash. So the
side effect doesn’t make an obstacle for the appropriate
and widespread use of GTN.
Discussion
Our present meta-analysis of RCTs evaluating the pro-
tective effect of GTN on PEP and the cannulaiton of
ducts shows that the use of GTN before procedure
was effective just in the prevention of PEP. Although
the sublingual route seems to be more effective than
the transdermal form, yet the number of those
enrolled patients in the former wasn’t enough (260
patients) compared with the latter (1266 patients) and
thus perhaps made it not convincing. More impor-
tantly, we found that it is mainly for the centers with
high incidence of post-ERCP pancreatitis that the pro-
tective role of GTN against PEP was exerted rather
than for the centers with low incidence of PEP, which
is especially of practical meaning for those centers
without experienced endoscopists and/or advanced
instruments.
Hitherto, the etiology of ERCP-induced pancreatitis is
not completely understood. The most commonly held,
but largely unproven, hypothesis is that the injury initi-
ating pancreatitis is predominantly mechanical, resulting
from cannulation-induced spasm of the sphincter of
Figure 4 This figure revealed the overall effect of GTN on the successful rate of cannulation.
Table 4 Meta-analysis of all seven included RCTs together with two articles only with abstract
Trials Subgroup(N) Risk ratio (95%) CI Z P value Heterogeneity
x2 P I2,%
The effect of GTN on the primary rate of cannulation
all forms# 7 studies(n = 1233) 1.02 [0.96, 1.07] 0.57 0.57 6.22 0.40 3.6
all forms* 5 studies(n = 900) 0.99 [0.93, 1.06] 0.32 0.75 2.41 0.66 0
sublingual form# 3 studies(n = 587) 1.01 [0.93, 1.09] 0.22 0.83 6.12 0.05 67.3
topical form 2 studies(n = 184) 1.04 [0.91, 1.19] 0.59 0.56 0.00 0.95 0
The effect of GTN on the overall rate of cannulation
all forms# 8 studies(n = 1376) 1.01 [0.99, 1.04] 1.01 0.31 8.87 0.26 21.1
all forms* 7 studies(n = 1294) 1.01 [0.99, 1.04] 1.04 0.30 8.98 0.17 32.3
sublingual form# 3 studies(n = 552) 1.06 [0.98, 1.15] 1.95 0.05 2.91 0.23 31.3
topical form 2 studies(n = 184) 1.01 [0.96, 1.06] 0.45 0.65 0.39 0.53 0
#: analysis with one or both of the two articles only with abstract available
*: analysis without the two articles only with abstract available
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Oddi and consequent temporary pancreatic duct
obstruction [1].
It was demonstrated that Glyceryl trinitrate (GTN), a
nitric oxide donor, lowered basal pressure and contrac-
tion amplitude in the sphincter of Oddi [6], an effect
that has been used to facilitate endoscopic removal of
medium- and small-sized stones from the biliary tract
[7]. In selected difficult cases GTN is occasionally admi-
nistered sublingually by some endoscopists to facilitate
cannulation [8].
But our analysis suggested that prophylactic use of
GTN before ERCP seems not to be helpful for increas-
ing the successful rate cannulation of bile ducts.
Furthermore, it can’t be able to help reduce the
attempts of cannulation, the time of procedure, or even
the use of pre-cut especially for topical and transdermal
route. Wehrmann T et al [12] reported that neither the
number of cannulation attempts nor the time until suc-
cessful cannulation differed significantly between the
groups and the pre-cut rate was nearly identical in the
two groups. Talwar A et al [17], topically administered
GTN to the sphincter of Oddi did not aid in obtaining a
cholangiogram or cannulation during an ERCP. How-
ever, the sublingual form of GTN seems to be relatively
effective in increasing the successful rate of cannulation.
Why does the sublingual form appear to be more
effective than the other forms? It seems that this phe-
nomenon can’t be explained clearly according to the
currently existing information.
There are some other agents reported for prophylactic
use before ERCP to reduce the incidence of PEP. Of
these, it was demonstrated that NSAIDs was effective in
the preventing PEP [5,19,20] and somatostatin and
gabexate seems not to be effective [21,22]. Badalov N et
al [4] reviewed the prophylactic using of all kinds of
agents. Firstly, regarding to drugs that decrease inflam-
mation, there was just NSAIDs showing clear benefits,
with other agents such as allopurinol, n-acetylcysteineIn,
corticosteroids and interleukin-10 (IL-10) showing no
clear benefits. Secondly, for drugs that interrupt the
activity of proteases including heparin, gabexate maleate
and ulinastatin, there are still no clear benefits detected.
Finally, inhibitors of pancreatic secretion including soma-
tostatin, calcitonin and glucagon showed no protective
effect for PEP, yet maybe octreotide and beta-carotine
administration had a beneficial effect. Additionally, pan-
creatic stent placement and guidewire cannulation seems
to be effective in the preventing PEP [23].
As was described above, there are two kinds of meta-
analysis-proved agents ef-fective in the preventing or
reducing the incidence of PEP, including NAIDs and
GTN. And prophylactic pancreatic stent placement was
one mechanically effective method, but it is not an easy
operation requiring a well-experienced physician, thus it
is less applied compared with pharmaceutical agents.
With the PEP still being the most dreadful complication
after ERCP, if we put the two ways of agents and stent-
placement together, maybe it can yield a more effective
way to overcome this dreadful complication of ERCP.
More importantly, the adverse effects of using GTN
prophylactically before the procedure of ERCP mainly
include hypotension and headache and they responded
to conventional treatment.
Compared with the previous studies, this systematic
meta-analysis had two main differences: First, compared
with Bai’s and Shao’s studies [24,26], this meta-analysis
included more RCTs; Second, in addition to the analysis
of effect of GTN on the incidence of PEP, this paper
also analyzed whether GTN was conducive to the can-
nulation of bile ducts, and all of other published articles
have not conducted any such analysis [24-26].
Conclusion
In conclusion, our study provides another pooled and
updated evidence of the benefits of GTN in preventing
post-ERCP pancreatitis and the first pooled evidence of
effect of GTN on the cannulation of ducts. This simple,
cheap, and safe medication of GTN, especially the sub-
lingual administration, is recommended for prophylactic
use before ERCP to prevent pancreatitis and reduce the
incidence of post-ERCP pancreatitis. Prophylactic GTN
can be used together with other agents such as NAIDs
or with pancreatic-stent placement for preventing PEP,
maybe yielding a more satisfactory outcome. So wide-
spread prophylactic administration of GTN may signifi-
cantly reduce the incidence of PEP, resulting in major
clinical and economic benefit especially for those centers
with a high incidence of PEP, because compared with
other prophylactic agents, GTN not only is effective and
can be expediently or easily administrated, but is cheap.
Given current scepticism regarding the efficacy of any
prophylactic medication for ERCP, additional multicen-
tre studies with a large sample are needed for confirm-
ing the effectiveness of GTN on preventing PEPs, prior
to widespread adoption of this strategy.
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